{"id":"surfactant-nebulisation","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient oxygen desaturation"},{"rate":null,"effect":"Airway obstruction"},{"rate":null,"effect":"Pulmonary inflammation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Pulmonary surfactant is a naturally occurring mixture of lipids and proteins that reduces surface tension in the alveoli, preventing alveolar collapse and improving lung compliance. Nebulisation allows direct delivery of exogenous surfactant to the respiratory tract, bypassing systemic absorption and maximizing local therapeutic effect. This approach is intended to treat conditions characterized by surfactant deficiency or dysfunction.","oneSentence":"Surfactant nebulisation delivers pulmonary surfactant directly to the lungs via inhalation to improve gas exchange and reduce respiratory distress.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:47.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Respiratory distress syndrome in premature infants"}]},"trialDetails":[{"nctId":"NCT04315636","phase":"PHASE3","title":"Surfactant Nebulization for the Early Aeration of the Preterm Lung","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-03-19","conditions":"Preterm Birth, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal","enrollment":32},{"nctId":"NCT03235986","phase":"PHASE2","title":"A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-08-28","conditions":"Neonatal Respiratory Distress Syndrome","enrollment":166},{"nctId":"NCT02825953","phase":"NA","title":"Does The Surfactant Administration by Aerosolization Effective?","status":"UNKNOWN","sponsor":"nihat demir","startDate":"2016-01","conditions":"Respiratory Distress Syndrome, Surfactant Administration by Aerosolization","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Surfactant nebulisation","genericName":"Surfactant nebulisation","companyName":"University of Zurich","companyId":"university-of-zurich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Surfactant nebulisation is used to treat conditions such as Neonatal Respiratory Distress Syndrome and Preterm Birth, particularly in preterm neonates. It involves administering a surfactant agent, specifically Curosurf, via nebulization to help alleviate respiratory distress.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}